2016 Press Releases

Webcast ImageWebcast
AVEO Oncology at the 2016 JMP Securities Life Sciences Conference (Replay)
06/22/16 at 11:00 a.m. ET
AVEO Oncology at the 2016 JMP Securities Life Sciences Conference
Wednesday, June 22, 2016 11:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
06/15/16AVEO to Present at the 2016 JMP Securities Life Science Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 15, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.D., Chief Medical Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 11:00 AM Eastern Time. The conference is being held at the St. Regis Hotel in New York. A live webcast can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. ... 
Printer Friendly Version
05/26/16AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 26, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Company’s pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). This Smart Ne... 
Printer Friendly Version
05/18/16AVEO Announces Closing of Private Placement and Amended Term Loan to Fund Pivotal TIVO-3 Trial and Combination PD-1 Trial of Tivozanib in Renal Cell Cancer
Private Placement Provides Gross Proceeds of Approximately $17 Million; Amended Term Loan to Provide up to $10 Million in Funding CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 18, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that it has closed its previously announced private placement of 17,642,482 units, consisting of one share of common stock and a warrant to purchase one share of common stock, at a price of $0.965 per unit, for gro... 
Printer Friendly Version
05/13/16AVEO Announces $17 Million Private Placement
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 13, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that it entered into a securities purchase agreement for a private placement with a select group of qualified institutional buyers, institutional accredited investors and accredited investors. The private placement will consist of 17,642,482 units, at a price of $0.965 per unit, for gross proceeds of approximately $17 million, before deducting placement agent fe... 
Printer Friendly Version
05/10/16AVEO Oncology Reports First Quarter 2016 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 10, 2016-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2016. “We achieved several important goals in the first quarter critical to advancing the corporate strategy we outlined early in 2015. This includes the submission and validation of an MAA filing in Europe for tivozanib in front-line RCC by our partner EUSA Pharma and the licensing of AV-203 ... 
Printer Friendly Version
05/02/16AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, the Company’s potent inhibitory antibody specific to Notch 3. These patent applications are the second set of applications related to AV-353 and the Company’s Notch 3 antibody program. The No... 
Printer Friendly Version
03/21/16AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North America
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Mar. 21, 2016-- AVEO Oncology (NASDAQ:AVEO) and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, today announced an exclusive collaboration and license agreement in which AVEO has granted CANbridge Life Sciences worldwide rights, excluding the United States, Canada, and Mexico, to AV-203, AVEO’s clinical-stage ErbB3 (HER3) inhibitor... 
Printer Friendly Version
03/15/16AVEO Oncology Reports Full Year 2015 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 15, 2016-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2015 and provided a business update. “Over the course of 2015, AVEO has streamlined its organization and taken a fresh strategic direction to create increased shareholder value. In 2016, we are squarely focused on furthering the execution of this strategy,” said Michael Bailey, president and chief ex... 
Printer Friendly Version
03/09/16AVEO to Present at the 28th Annual ROTH Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 9, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 28th Annual ROTH Conference on Wednesday, March 16, 2016, at 9:00 a.m. Pacific Time. The conference is being held at The Ritz Carlton Hotel in Dana Point, CA. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website a... 
Printer Friendly Version
03/01/16EUSA Pharma and AVEO Announce Submission of Marketing Authorization Application for Tivozanib in Advanced Renal Cell Carcinoma
HEMEL HEMPSTEAD, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 1, 2016-- EUSA Pharma, a newly-established specialty pharmaceutical business, and AVEO Oncology (NASDAQ:AVEO) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for tivozanib for the first-line treatment of advanced renal cell carcinoma (RCC). The filing is based on tivozanib’s existing dataset and follows positive interactio... 
Printer Friendly Version
02/22/16AVEO Announces Acceptance of Registration Dossier for Tivozanib in RCC by the Ministry of Health of the Russian Federation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 22, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that a registration dossier seeking to obtain marketing authorization of tivozanib as a first line treatment of advanced renal cell carcinoma (“RCC”) has been accepted by the Ministry of Health (“MoH”) of the Russian Federation. The dossier was submitted in December 2015 by Pharmstandard Group, the largest Russian pharmaceutical group (“Pharmstandard”). In Augu... 
Printer Friendly Version
02/02/16AVEO to Present at the 18th Annual BIO CEO & Investor Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 9:00 a.m. Eastern Time. The conference is being held at The Waldorf Astoria hotel in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section... 
Printer Friendly Version
01/06/16AVEO to Present at Biotech Showcase 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at Biotech Showcase 2016 on Wednesday, January 13, 2016 at 4:00 PM (PT) at the Parc 55 Wyndham in San Francisco. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at www.aveooncology.com. A replay of the webcas... 
Printer Friendly Version